Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi

Anıl Tombak, M.D., Mersin University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Mersin, Turkey

Received/Geliş tarihi: January 3, 2021
Accepted/Kabul tarihi: August 16, 2021

Address for Correspondence/Yazışma Adresi: Anıl Tombak, M.D., Mersin University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Mersin, Turkey
Phone: +90 532 346 07 67
E-mail: aniltombak@mersin.edu.tr ORCID: orcid.org/0000-0002-7195-1845

DOI: 10.4274/tjh.galenos.2021.2021.0007
Turk J Hematol 2021;38:273-285
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients.

Materials and Methods: A total of 136 patients (mean age ± standard deviation: 64.6±10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed.

Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p=0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5).

Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.

Keywords: Chronic lymphocytic leukemia, Ibrutinib, Bruton’s tyrosine kinase inhibitor

Introduction

Owing to novel therapeutics such as combination chemotherapy with fludarabine and cyclophosphamide (FC) and chemoimmunotherapy with rituximab (FCR), the survival outcome and long-term remission rates of chronic lymphocytic leukemia (CLL) patients have improved significantly over the last decade, particularly in younger, low-risk CLL patients [1,2,3,4,5]. However, older patients with higher-risk genetic abnormalities or del(17p) still have inferior survival outcomes, while significant toxicities of chemotherapeutic regimens and poor survival rates with the use of conventional salvage regimens following relapse after FCR are also considered challenging factors in the management of CLL [3,4,6,7,8].

Given the importance of B-cell-receptor signaling in CLL and the central role of Bruton’s tyrosine kinase (BTK) in this pathway, targeted therapy with kinase inhibitors has become an alternative to conventional therapy for CLL [9,10,11]. The introduction of ibrutinib, an irreversible inhibitor of BTK, enabled significant improvement in the survival outcomes of CLL patients [10,11]. The results from three phase III trials demonstrated improved progression-free survival (PFS) and overall survival (OS) with ibrutinib compared to FCR or chlorambucil [12,13,14], while data from the RESONATE trial indicated the association of ibrutinib with significantly improved PFS, OS, and overall response rate (ORR) when compared to ofatumumab in previously treated CLL patients with several high-risk prognostic factors [15]. Accordingly, ibrutinib has become the standard of care in...
Ibrutinib experience in patients with CLL: relapsed/refractory patients and is now being recommended for use in front-line treatment of patients regardless of age or del(17p) status [16,17,18,19,20,21].

Given the potential differences in baseline characteristics and treatment responses of patients recruited in clinical trials and those treated outside of clinical trials, there is considerable interest in real-world experience with the use of novel targeted drugs in the management of CLL patients, particularly for drugs such as ibrutinib that are recommended to be used continuously until progression [10,22,23,24,25]. This real-life multicenter study was therefore designed to retrospectively evaluate efficacy and safety along with survival outcomes of single-agent ibrutinib therapy in CLL patients who were treated outside the setting of clinical trials.

Materials and Methods

Study Population

A total of 136 adult patients diagnosed with CLL (≥18 years old; mean age ± standard deviation: 64.6±10.3 years; 66.9% male patients) who had received at least one dose of single-agent ibrutinib therapy after January 2013 were included in this retrospective multicenter, noninterventional hospital-registry study conducted between December 2018 and March 2019 at 33 centers across Turkey. Patients who had sensitivity to an active ingredient or component of the medication or who had ibrutinib treatment before December 2012 were excluded.

The study was conducted in full accordance with local good clinical practice guidelines and current legislations, while permission was obtained from the relevant institutional ethics committee for the use of patient data for publication purposes.

Data Collection

Data on patient demographics (age, gender), baseline characteristics (comorbidity, bulky disease, organomegaly, infection, Eastern Cooperative Oncology Group [ECOG] performance status, Rai stage, previous treatments), and laboratory findings including hemoglobin, platelet count, leukocyte count, lymphocyte count, erythrocyte sedimentation rate, lactate dehydrogenase level, beta-2 microglobulin and IgG levels, Coombs test, and leukemia-cell cytogenetics (metaphase karyotyping, interphase fluorescence in situ hybridization [FISH] analysis) were retrieved from hospital records. Treatment responses including partial response (PR), complete response (CR), stable disease (SD), and progressive disease as well as final treatment response (PR and CR) were evaluated according to the relevant International Workshop Group on CLL response criteria [25]. Assessment of response was performed at least 2 months after achieving "maximum response". The OS (duration, rate), PFS (duration, rate), and adverse events (AEs) were also analyzed for patients who received single-agent ibrutinib treatment within the study period. PFS was defined as the period from the date of ibrutinib initiation to the first recurrence/death or the last follow-up. OS was defined as the period from the date of diagnosis to death or last follow-up.

Statistical Analysis

Statistical analysis was conducted using IBM SPSS Statistics 22.0 for Windows (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to summarize baseline characteristics. Pearson's chi-square ($\chi^2$) test was used for the comparison of categorical data. Survival analysis was performed via Kaplan-Meier analysis and comparisons were made via log-rank test. Data were expressed as mean ± standard deviation, median (minimum-maximum), 95% confidence interval (CI), and/or percentage (%) as appropriate.

Results

Baseline Characteristics

The mean patient age was 64.6±10.3 (range: 39-94) years and 61.9% of patients were male. Diabetes mellitus (25.7%) and hypertension (22.9%) were the most common comorbidities, while hepatosplenomegaly was noted in 33.8% of patients. Overall, 36.7% of patients were categorized as ECOG performance status class 2-3 and 44.9% were in Rai stage 4 (44.9%), while FISH testing revealed the presence of del(17p) in 39.8% of the patients (Table 1).

Prior Lines of Therapy and Related Treatment Responses

Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. CR rates were 27.8%, 32.8%, 10.7%, and 15.4% for patients having received 1, 2, 3, and ≥4 lines of prior therapy (Table 2).

Characteristics of Ibrutinib Therapy

For the majority of patients, ibrutinib was administered orally at a daily dose of 420 mg. The treatment indications were B signs and stage 4 disease in 52.2% and 41.2% of patients, respectively (Table 3).

Median duration of ibrutinib therapy was 8.8 months (range: 0.4-58.0 months), while dose reduction, dose delay, treatment discontinuation, and AEs occurred in 16.9%, 26.5%, 24.3%, and 54.4% of patients, respectively (Table 3).

Lymphocyte counts increased within the first month of treatment, followed by a gradual decrease starting from the second month and resolving at the sixth month (Table 3).
Treatment Response and Survival Outcome with Respect To Prognostic Factors

Final treatment response (CR or PR) was better in patients with 0-2 lines versus 3-7 lines of prior therapy (79.3% vs. 41.5%, p<0.001), in patients with ECOG performance status class 0-1 versus class 2-3 (75.0% vs. 50.0%, p=0.006), and in patients with Rai stage 0-2 versus 3-4 (88.9% vs. 57.0%, p=0.002). No significant difference was noted in final treatment response rates with respect to presence of comorbidity, bulky disease, or del(17p) status (Table 4).

After a median of 69.0 (range: 9.0–296.0) months of follow-up, mortality had occurred for 29 of 136 patients (21.3%), while 107 (81.3%) patients survived. Sepsis (31.0%) was the most common cause of death, followed by cardiac arrest (13.8%), pneumonia (10.3%), and Richter’s syndrome (10.3%) (Table 5).

Overall, 1-year PFS and OS rates were 82.2% and 84.6%, respectively (Table 5), while median (standard error [SE], 95% CI) PFS time was 30.0 (5.1, 20.0–40.0) months and median (SE, 95% CI) OS time was 37.9 (3.2, 31.5–44.2) months (Table 6, Figure 1).

Mean PFS time was longer in patients with 0-2 lines versus 3-7 lines of prior therapy (39.2±4.4 vs. 20.5±2.9 months, log-rank p=0.001, Figure 2), in patients with ECOG performance status class 0-1 versus class 2-3 (42.5% vs. 26.2%, p=0.012), and in patients with Rai stage 0-2 versus 3-4 (48.9% vs. 23.5%, p=0.001). No significant difference was noted in final treatment response rates with respect to presence of comorbidity, bulky disease, or del(17p) status (Table 4).

Table 1. Baseline characteristics of patients.

| Patient demographics | Mean ± SD   | Gender, n (%) | Clinical findings | ECOG status | Rai stage |
|----------------------|-------------|---------------|------------------|-------------|-----------|
| Age (years)          | 64.6±10.3   | Male 91 (66.9) | Diabetes mellitus | 1           | 0-2       |
|                      |             | Female 45 (33.1) | Hypertension     | 2           | 3-7       |
|                      |             |                | Coronary artery disease | 0          |           |
|                      |             |                | Hepatitis B infection | 1          |           |
|                      |             |                | Other (each <3%)  | 2           |           |
|                      |             |                | Bulky disease     | 2           |           |
|                      |             |                | Organomegaly      | 4           |           |
|                      |             |                | Hepatosplenomegaly | 6           |           |
|                      |             |                | Splenomegaly      | 8           |           |
|                      |             |                | Hepatomegaly      | 10          |           |
|                      |             |                | Infection         | 13          |           |
|                      |             |                | Urinary tract infection | 22         |           |
|                      |             |                | ECOG status       | 5           |           |
|                      |             |                | Rai stage         | 3           |           |
|                      |             |                | Laboratory findings | 5           |           |
|                      |             |                | Hemoglobin        | 1             |           |
|                      |             |                | Platelets         | 2             |           |
|                      |             |                | Leukocytes        | 3             |           |
|                      |             |                | Lymphocytes       | 4             |           |
|                      |             |                | LDH               | 5             |           |
|                      |             |                | Beta-2 microglobulin | 6           |           |
|                      |             |                | ESR               | 7             |           |
|                      |             |                | IgG               | 8             |           |
|                      |             |                | Coombs test       | 9             |           |
|                      |             |                | Cytogenetic       | 10            |           |
|                      |             |                | FISH              | 11            |           |

SD: Standard deviation; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; ESR: erythrocyte sedimentation rate; IgG: immunoglobulin G; FISH: fluorescence in situ hybridization; min: minimum; max: maximum.

Missing data for 1, 46, 2 (also excluding 3 patients with first-line ibrutinib therapy), 10, 27, and 44 patients.

Table 2. Prior lines of therapy and related treatment responses.

| Number of prior lines of therapy | Median (min-max) |
|----------------------------------|------------------|
| None                             | 2.0 (0.0–7.0)    |
| 1                                | 6.0 (0.0–120.0)  |

| Treatment response | CR | PD | PR | SD | Total |
|--------------------|----|----|----|----|-------|
| Last treatment response before ibrutinib² | 19 (14.0) | 30 (22.1) | 65 (47.8) | 17 (12.5) | 131 (100.0) |
| Prior lines of therapy | None | 2 (66.7) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 3 (2.4) |
| 1¹ | 5 (27.8) | 3 (16.7) | 9 (50.0) | 1 (5.6) | 18 (14.6) |
| 2¹ | 20 (32.8) | 7 (11.5) | 28 (45.9) | 6 (9.8) | 61 (49.6) |
| 3¹ | 3 (10.7) | 13 (46.4) | 7 (25.0) | 5 (17.9) | 28 (22.8) |
| >4 | 2 (15.4) | 6 (46.2) | 5 (38.5) | 0 (0.0) | 13 (10.6) |
| Total | 32 (26.0) | 29 (23.6) | 50 (40.7) | 12 (9.8) | 123 (100.0) |

PR: Partial response; CR: complete response; PD: progressive disease; SD: stable disease; min: minimum; max: maximum.
Tombak A. et al: Ibrutinib Experience in Patients with CLL

Mean OS time was also longer in patients with 0–2 lines versus 3–7 lines of prior therapy (45.9±4.19 vs. 22.1±3.1 months, log-rank p<0.001, Figure 2), in patients with ECOG performance status class 0–1 versus class 2–3 (43.7±3.9 vs. 22.1±3.49 months, log-rank p=0.001, Figure 3), and in patients with Rai stage 0–2 versus 3–4 (52.0±4.1 vs. 28.6±3.4 months, log-rank p=0.002, Figure 4) (Table 6).

No significant difference was noted in PFS time and OS time with respect to presence of comorbidity, bulky disease, del(17p) status, or overall FISH findings (Table 6).

Safety Profile

Overall, 176 AEs were reported in 74 (54.4%) patients, and 46 of those 176 AEs were grade 3–4 AEs, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5) in most cases. The atrial fibrillation rate was low (n=2) (Table 7).

Discussion

Our findings revealed the favorable efficacy and safety profile of ibrutinib in CLL patients (mean age of 64.6 years, del(17p) mutation in 28.7%, Rai stage 3/4 in 68.4%) with 1-year PFS and OS rates of 82.2% and 84.6% at a median follow-up of 69.0 months, respectively. The final treatment response (CR or PR) was better and survival times (PFS and OS) were longer for patients with fewer than <2 lines of prior therapy, ECOG performance class 0–1, and Rai stage 0–2 while there was no significant impact of comorbidity, bulky disease, or del(17p) status on treatment response or survival outcomes.

Table 3. Characteristics of ibrutinib therapy.

| Dose, n (%) |   |
| 420 mg | 131 (96.3) |
| 280 mg | 3 (2.2) |
| 140 mg | 2 (1.5) |
| Treatment indication, n (%) |   |
| Stage 4 disease | 56 (41.2) |
| Stage 3 disease | 29 (21.3) |
| Rapid doubling time | 22 (16.2) |
| B signs | 71 (52.2) |
| Bulky disease | 12 (8.8) |
| Richter’s syndrome | 4 (2.9) |
| Rapidly progressive disease | 1 (0.7) |
| Treatment duration (months) |   |
| Mean ± SD | 12.2±11.1 |
| Median (min–max) | 8.0 (0.4–58.0) |
| Number of treatment cycles (n=133) |   |
| Mean ± SD | 11.2±10.5 |
| Median (min–max) | 8 (1–58) |
| Dose reduction, n (%) (n=135) | 23 (16.9) |
| Dose delay, n (%) (n=136) | 36 (26.5) |
| Discontinuation, n (%) (n=111) | 33 (24.3) |
| Adverse events, n (%) | 74 (54.4) |

SD: Standard deviation; min: minimum; max: maximum.
Figure 2. One-year progression-free survival (PFS) and overall survival (OS) rates in patients with 0-2 lines versus 3-7 lines of prior therapy.

Figure 3. One-year progression-free survival (PFS) and overall survival (OS) rates in patients with Eastern Cooperative Oncology Group (ECOG) performance status class 0-1 versus class 2-3.

Figure 4. One-year progression-free survival (PFS) and overall survival (OS) rates in patients with Rai grade 0-2 versus 3-4.
Data from a real-life retrospective study including 32 ibrutinib-treated patients (11 had CLL) in Turkey revealed that in patients with CLL, ibrutinib treatment (median: 4 months) was associated with an ORR of 85.6% (28.5% CR and 57.1% PR) and occurrence of diarrhea in 3 (27.3%), pneumonia in 3 (27.3%), and thrombocytopenia and/or neutropenia in 2 (18.2%) patients [26]. The authors considered ibrutinib a good treatment option for CLL and other B-cell lymphomas, with an acceptable side-effect profile and a high and promising CR/PR response rate [26].

Similarly, according to real-life data from the UK CLL Forum obtained from 315 CLL patients with a median of 16 months of follow-up, the authors noted 1-year discontinuation-free survival (DFS) of 73.7% and 1-year OS of 83.8% with no significant difference in DFS and OS rates with respect to del(17p) status, whereas there was an association of better pre-treatment performance status (0/1 vs. 2+) with superior DFS (77.5% vs. 61.3%) and OS (86.3% vs. 76.0%) and an association of 1 prior line of therapy versus 2+ prior lines of therapy with a significant 1-year PFS advantage (94% vs. 82%) [22]. The same authors also noted no significant difference between more or less heavily pre-treated patients in terms of prognostic factors such as performance status and del(17p), while emphasizing the likelihood of older patients and those with del(17p) to have inferior DFS and OS when treated with ibrutinib beyond the second line [22].

In a multicenter Swedish study providing real-life data from 95 CLL patients (median age: 69 years, del(17p)/TP53 mutation in 63%, Rai stage 3/4 in 65%), the authors reported that once-a-day ibrutinib treatment was well tolerated and associated with an ORR of 84%, PFS of 77%, and OS rate of 83% at a median follow-up of 10.2 months [23]. However, in contrast to our findings, the authors indicated that del(17p)/TP53 mutation remained a therapeutic challenge given the significantly shorter PFS and OS in patients with del(17p)/TP53 mutation [23].

In addition, data from a mutation analysis study of 63 patients who were still on ibrutinib after 3 years in an early-access program at 29 French centers revealed detection of BTK and PLCG2 mutations in 57% and 13% of the next-generation sequencing samples (n=30) and the authors reported that after a median follow-up of 8.5 months from sample collection, the presence versus the lack of a BTK mutation was significantly associated with subsequent CLL progression [27]. The same authors emphasized a need for clinical trials to evaluate whether patients with BTK mutation may benefit from an early switch to another treatment [27].

In a real-life study on the efficacy of ibrutinib as a single agent in 180 patients with CLL recruited from three independent cohorts from Italy, 73 patients were reported to have discontinued

| Table 4. Treatment response with respect to prognostic factors. |
|---------------------------------------------------------------|
| Ibrutinib-treated patients (n=136)* | Final treatment response | Total | p |
|-------------------------------------|--------------------------|-------|---|
|                                     | (CR or PR)               |       |   |
|                                     | No  | Yes |       |     |   |
| Pre-ibrutinib lines of therapy      |     |     |       |     |   |
| 0-2                                 | 17 (20.7) | 65 (79.3) | 82 | <0.001 |
| 3-7                                 | 24 (58.5) | 17 (41.5)  | 41 |       |
| Total                               | 41  | 82  | 123 |     |   |
| 17p deletion                        |     |     |       |     |   |
| Present                             | 13 (35.1) | 24 (64.9)  | 37 | 0.409 |
| Absent                              | 27 (43.5) | 35 (56.5)  | 62 |       |
| Total                               | 40  | 59  | 99  |     |   |
| ECOG                                |     |     |       |     |   |
| 0 or 1                              | 18 (25.0) | 54 (75.0)  | 72 | 0.006 |
| 2 or 3                              | 22 (50.0) | 22 (50.0)  | 44 |       |
| Total                               | 40  | 76  | 116 |     |   |
| Rai                                 |     |     |       |     |   |
| 0-2                                 | 3 (11.1)  | 24 (88.9)  | 27 | 0.002 |
| 3-4                                 | 37 (43.0) | 49 (57.0)  | 86 |       |
| Total                               | 40  | 73  | 113 |     |   |
| Comorbidity                         |     |     |       |     |   |
| Present                             | 24 (38.1) | 39 (61.9)  | 63 | 0.197 |
| Absent                              | 16 (27.1) | 43 (72.9)  | 59 |       |
| Total                               | 40  | 82  | 122 |     |   |
| Bulky disease                       |     |     |       |     |   |
| Present                             | 9 (36.0)  | 16 (64.0)  | 25 | 0.751 |
| Absent                              | 32 (32.7) | 66 (67.3)  | 98 |       |
| Total                               | 41  | 82  | 123 |     |   |

*Missing data for 13 patients.  
Pearson chi-square.
ibrutinib for progression or for AEs, while NOTCH1-mutated patients were reported to have less redistribution lymphocytosis at 3 months on ibrutinib, to show inferior nodal response at 6 months, and to have significantly shorter PFS and OS [28]. The same authors noted that NOTCH1 M plus lower BAX/BCL-2 ratio identified a CLL subset showing the worst PFS and OS, emphasizing the likelihood of either new small-molecule combination approaches or antibodies targeting NOTCH1 being more appropriate therapeutic options for NOTCH1-mutated patients [28].

Notably, based on data from a study conducted in Poland on the potential significance of the mutational status of 30 selected genes for disease outcome in a real-life cohort of 45 heavily pretreated patients with CLL, the authors reported that despite the accumulation of several poor prognostic factors such as TP53 (40.0%), NOTCH1 (28.8%), SF3B1 (24.4%), ATM (15.6%), MED12 (13.3%), CHD2 (11.1%), XPO1 (11.1%), NFKBIE (11.1%), BIRC3 (8.9%), SPEN (8.9%), POT1 (8.9%), EGR2 (6.7%), and RPS15 (6.7%) in their cohort, ibrutinib treatment showed long-term clinical benefits in terms of 36-month PFS (64.0%) and OS (68.2%) rates and the ORR (51.1%) [29].

Higher treatment response and better PFS and OS outcomes in patients previously treated with 0-2 lines of therapy versus more heavily treated patients in the current study seem to be consistent with data from other real-life studies [22]. Fewer lines of prior therapy were also reported to be associated with significantly improved PFS and OS outcomes and higher CR rates and 5-year PFS and OS rates in treatment-naïve (TN) patients compared to relapsed/refractory (R/R) patients, emphasizing the deepening of responses with continued ibrutinib therapy and the likelihood of superior efficacy of initiating ibrutinib in earlier lines of therapy [16].

Dose reduction (16.9%), dose delay (26.5%), and treatment discontinuation (24.3%) rates in the current study also seem to be consistent with previous real-life data on ibrutinib discontinuation rates (10.5% to 17.5%), dose reductions (26.0%), and temporary treatment breaks (>14 days, 13.0%) or permanent treatment discontinuation (17.5% to 41%) [22,23,30,31]. Notably, neither the dose reductions nor the temporary treatment breaks were reported to be associated with survival outcome, whereas permanent cessation of ibrutinib was associated with reduced 1-year OS survival [22]. Similar to our findings, poorer 1-year DFS (16.2%) and OS (9.3%) in patients with poorer pre-treatment performance status (PS 2+) were reported while also noting a higher likelihood of treatment breaks within the first year of therapy in the PS 2+ group [22].

In a recent FILO Group study on the OS benefits of symptom monitoring in real-world CLL patients treated with ibrutinib, the authors reported that drug intolerance and toxicities (26.3%) rather than progressive disease accounted for most drug withdrawals [27] and they indicated the higher likelihood of stopping ibrutinib due to toxicities in the real-life setting when compared to ibrutinib discontinuation rates due to toxicity (10%) and CLL progression (13.5%) as reported in RESONATE and RESONATE-2 pooled analysis [32]. The potential role of certain factors in this discrepancy has been suggested, such as the clinical experience of physicians in managing toxicity, the availability of alternative therapy, and the characteristics of real-life populations in terms of performance status and comorbidities [31].

In a recent French study on patterns of use and safety of ibrutinib in real-life practice in 102 patients, half of whom were CLL patients, the authors reported that 42.1% of patients permanently discontinued ibrutinib in the first year, mostly for progression (51.2%) or adverse drug reactions (ADRs) (32.6%), while 47.1% of patients experienced at least one ibrutinib-associated serious ADR (SADR; hematological, infectious, and vascular disorders in particular) [33]. These authors also reported the probability of developing an ibrutinib-associated SADR to be 35.1% (95% CI: 26.3-45.7) at 3 months, 44.8% (95% CI: 35.2-55.8) at 6 months, and 54.3% (95% CI: 44.0-65.2) at 12 months, further indicating a significant association of age of ≥80 years (hazard ratio [HR]: 2.03; 95% CI: 1.02-4.05) and being treated for CLL (HR: 1.81; 95% CI: 1.01-3.25) with a higher risk of SADR occurrence [33].

---

**Table 5. Survival outcome with respect to prognostic factors.**

| Duration of follow-up, median (min-max) | 69.0 (9.0-296.0) |
| Survivor, n (%)   | 107 (78.7) |
| Non-survivor, n (%) | 29 (21.3) |
| **Cause of death, n (%)** | |
| Sepsis            | 9 (31.0) |
| Cardiac arrest    | 4 (13.8) |
| Pneumonia         | 3 (10.3) |
| Richter’s syndrome | 3 (10.3) |
| Sudden death      | 1 (3.4) |
| Cerebral hemorhage | 1 (3.4) |
| Fungal sinusitis and pneumonia | 1 (3.4) |
| Mucor infection   | 1 (3.4) |
| Cerebral aspergilosis | 1 (3.4) |
| Respiratory arrest | 1 (3.4) |
| Stroke            | 1 (3.4) |
| Total             | 26 |
| Missing           | 3 |

**One-year survival rate (%)**

- PFS: 82.2%
- OS: 84.6%

PFS: Progression-free survival; OS: overall survival; min: minimum; max: maximum.
Based on data from a Greek single-center retrospective real-world study including 58 CLL patients (11 first-line, 47 R/R) treated with ibrutinib monotherapy (for a median of 6.6 and 16.3 months, respectively), treatment discontinuation was reported to be associated with AEs (due to atrial fibrillation in 3.5% of patients) in 9% of the first-line and 10.6% of the R/R patients, while it was due to disease progression in 13 (24.5%) patients [34]. These authors concluded that CLL patients had outcomes similar to those of clinical trials if treated homogeneously according to standard guidelines, resulting in fewer unneeded discontinuations and shrinkage of the treatment armamentarium [34]. The superior efficacy of ibrutinib with significantly improved ORR, PFS, and OS compared to ofatumumab in R/R patients or compared to chlorambucil as frontline therapy in TN patients was established in the RESONATE trials, which included extended follow-up analyses [9,13,15,24,35,36,37,38]. Accordingly, our findings support favorable treatment responses and survival outcomes with the use of off-trial ibrutinib, similar to data from multicenter prospective pivotal trials on ibrutinib, despite the fact that patients included in the pivotal clinical trials were often younger, had better ECOG classifications, and presented with milder lymphadenopathy [22,23]. Nonetheless, our findings support the potential roles of poorer ECOG performance status and having been heavily treated before ibrutinib in the likelihood of observing higher treatment discontinuation rates and inferior survival outcome in real-world settings, given the more stringent rules for dose modifications or interruptions and thus higher levels of drug compliance in clinical trials [22].

While del(17p) status had no significant impact on survival outcome in the current study, poorer survival outcome was reported for patients with del(17p) in the 3-year follow-up of a phase 1b–2 multicenter study [37] and in the RESONATE-17 study [39], as well as in a real-life study [23]. However, subgroup analysis of the RESONATE study also showed that the presence of del(17p) was not associated with inferior PFS outcomes with similar ORRs (89% and 91%, respectively) and 18-month PFS rates (71% and 79%, respectively) in patients with del(17p).

### Table 6. Further analysis of survival outcome with respect to prognostic factors.

|                | Progression-free survival time (months) | Overall survival time (months) |
|----------------|------------------------------------------|--------------------------------|
|                | Mean | SD  | 95% CI | Median | SE  | 95% CI | Mean | SD  | 95% CI | Median | SE  | 95% CI |
| Overall        | 33.3 | 3.1 | 27.2   | 39.5   | 30.0 | 5.1 | 20.0  | 40.0  | 37.9 | 3.2 | 31.5   | 44.2   | -    | -     |
| Lines of pre-ibrutinib therapy |       |      |        |        |      |    |       |       |      |    |        |        |      |       |
| 0–1–2          | 39.2 | 4.4 | 30.5   | 47.9   | -    | -  | -     | -     | 45.9 | 4.1 | 37.9   | 53.9   | -    | -     |
| 3–4–5–6–7      | 20.5 | 2.9 | 14.9   | 26.2   | 17.1 | 2.6 | 12.1  | 22.1  | 22.1 | 3.1 | 16.0   | 28.1   | 17.1 | 3.4   |
| p1             | <0.001 |      |        |        |      |    |       |       |      |    |        |        |      |       |
| 17p deletion   |      |      |        |        |      |    |       |       |      |    |        |        |      |       |
| Present        | 20.05 | 2.9 | 14.3   | 25.7   | 14.1 | 4.4 | 5.4   | 22.7  | 22.1 | 3.2 | 15.7   | 28.4   | 19.4 | 4.3   |
| Absent         | 33.8 | 4.2 | 25.7   | 42.0   | 30.7 | 7.6 | 15.8  | 45.5  | 40.0 | 4.0 | 32.1   | 47.8   | .    | .     |
| p1             | 0.224 |      |        |        |      |    |       |       |      |    |        |        |      |       |
| ECOG status    |      |      |        |        |      |    |       |       |      |    |        |        |      |       |
| 0 or 1         | 37.0 | 4.0 | 29.1   | 44.8   | 30.0 | -   | -     | -     | 43.7 | 3.9 | 36.1   | 51.3   | -    | -     |
| 2 or 3         | 21.7 | 3.3 | 15.3   | 28.1   | 23.9 | 7.4 | 9.3   | 38.5  | 22.1 | 3.4 | 15.4   | 28.8   | 17.1 | 5.0   |
| p1             | 0.011 |      |        |        |      |    |       |       |      |    |        |        |      | 0.001 |
| Rai            |      |      |        |        |      |    |       |       |      |    |        |        |      |       |
| 0, 1, 2        | 47.5 | 5.4 | 36.9   | 58.19  | .    | .   | .     | .     | 52.0 | 4.1 | 43.9   | 59.9   | .    | .     |
| 3, 4           | 24.7 | 3.0 | 18.9   | 30.6   | 22.4 | 4.7 | 13.3  | 31.5–6| 28.6 | 3.4 | 22.1   | 35.2   | 30.0 | 11.1  |
| p1             | 0.001 |      |        |        |      |    |       |       |      |    |        |        |      | 0.002 |
| Comorbidities  |      |      |        |        |      |    |       |       |      |    |        |        |      |       |
| Present        | 26.6 | 3.3 | 20.1   | 33.0   | 22.4 | 4.0 | 14.6  | 30.3  | 29.4 | 3.6 | 22.4   | 36.4   | 23.9 | 8.0   |
| Absent         | 39.5 | 4.9 | 29.8   | 49.1   | .    | .   | .     | .     | 45.5 | 4.5 | 36.8   | 54.2   | .    | .     |
| p1             | 0.203 |      |        |        |      |    |       |       |      |    |        |        |      | 0.074 |
| Bulky disease  |      |      |        |        |      |    |       |       |      |    |        |        |      |       |
| Present        | 26.6 | 3.0 | 20.7   | 32.5   | 30.0 | 4.7 | 20.8  | 39.2  | 26.2 | 3.0 | 20.3   | 32.2   | 30.0 | 4.7   |
| Absent         | 32.3 | 3.5 | 25.5   | 39.1   | 22.4 | 7.5 | 7.8   | 37.1  | 38.3 | 3.6 | 31.3   | 45.38  | .    | .     |
| p1             | 0.543 |      |        |        |      |    |       |       |      |    |        |        |      | 0.918 |

SD: Standard deviation; CI: confidence interval; LB: lower bound; UB: upper bound; ECOG: Eastern Cooperative Oncology Group.
and those without del(17p) [35]. Likewise, 3-year PFS in ibrutinib-treated CLL patients was reported to be 53% for patients with del(17p), 66% for those with del(11q), and 58% for patients without these abnormalities [40]. In a phase 1b-2 multicenter study of 85 CLL patients, the authors reported ibrutinib to promote durable responses irrespective of the dose, with similar ORRs (71%) in the 420-mg and 840-mg cohorts along with 26-month PFS and OS rates of 75% and 83%, respectively [11]. The authors also noted no significant impact of traditional high-risk prognostic features, including del(17p), on the treatment response rates [11].

Notably, del(17p) has been suggested to be a poor prognostic factor in patients who receive frontline ibrutinib with no negative impact of del(17p) on OS in the R/R setting, while R/R disease, age, performance status, and comorbidities were reported as determinants of poor OS in ibrutinib-treated patients with CLL [41]. Moreover, the frequency of high-risk genomic abnormalities including del(17p) has been suggested to dramatically increase with increasing lines of chemotherapy, and treatment with single-agent ibrutinib earlier in the disease course before the development of these abnormalities has therefore been considered to improve patient outcomes [16].

Table 7. Safety profile.

| AE            | # of AEs | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---------------|----------|---------|---------|---------|---------|---------|
| Tiredness     | 29       | 24      | 5       | -       | -       | -       |
| Anemia        | 19       | 6       | 8       | 4       | 1       | -       |
| Pneumonia     | 19       | 1       | 6       | 11      | 1       | -       |
| Neutropenia   | 18       | 3       | 4       | 6       | 5       | -       |
| Diarrhea      | 17       | 11      | 6       | -       | -       | -       |
| Thrombocytopenia | 10  | 1       | 4       | 4       | 1       | -       |
| Rash          | 7        | 5       | 2       | -       | -       | -       |
| Decreased appetite | 6    | 5       | 1       | -       | -       | -       |
| Fever         | 6        | 1       | -       | 5       | -       | -       |
| Arthralgia    | 6        | 1       | 5       | -       | -       | -       |
| Nausea        | 6        | 5       | 1       | -       | -       | -       |
| ALT/AST elevation | 4   | 4       | -       | -       | -       | -       |
| Gastrointestinal complaints | 3   | 1       | 2       | -       | -       | -       |
| Stomatitis    | 2        | 1       | 1       | -       | -       | -       |
| Itching       | 2        | 1       | -       | 1       | -       | -       |
| Lymphopenia   | 2        | 1       | 1       | -       | -       | -       |
| Neutropenic fever | 2  | -       | -       | 2       | -       | -       |
| Arrhythmia    | 2        | -       | 2       | -       | -       | -       |
| Eye complaints | 2    | 2       | -       | -       | -       | -       |
| Atrial fibrillation | 2  | -       | 2       | -       | -       | -       |
| Hypothyroidism | 1    | 1       | -       | -       | -       | -       |
| Elevated creatinine | 1   | 1      | -       | -       | -       | -       |
| Intracranial hemorrhage | 1  | -       | -       | -       | -       | 1       |
| Deep vein thrombosis | 1   | -       | -       | 3       | -       | -       |
| Muscle cramps  | 1        | -       | 2       | -       | -       | -       |
| Ataxia        | 1        | 1       | -       | -       | -       | -       |
| Confusion     | 1        | 1       | -       | -       | -       | -       |
| Dyspnea       | 1        | 1       | -       | -       | -       | -       |
| Cough         | 1        | -       | -       | 1       | -       | -       |
| Fungal infection | 1   | -       | -       | 1       | -       | -       |
| Cellulitis    | 1        | -       | 2       | -       | -       | -       |
| Hyperpigmentation | 1  | 1       | -       | -       | -       | -       |
| Zona          | 1        | 1       | -       | -       | -       | -       |

AEs: Adverse events; ALT: aspartate transaminase; AST: alanine transaminase.
Indeed, targeted therapies such as ibrutinib are considered to challenge the value of classic prognostic factors defined in the original CLL International Prognostic Index, emphasizing the need for new risk models applicable to CLL patients treated with all currently approved targeted therapies [41,42,43,44].

In the current study, lymphocyte counts increased within the first month of treatment, followed by a gradual decrease starting from the second month. This is consistent with the transient increase in absolute lymphocyte count expected within the first few weeks of ibrutinib therapy, which may persist for several weeks of treatment and does not signify disease progression [24,45]. Nonetheless, some authors reported the association of prolonged treatment-related lymphocytosis with higher likelihood of ibrutinib responders to carry favorable prognostic markers (i.e., del13q and mutated IGHV) and a trend toward improved PFS [35,45], while more rapid and more frequent normalization of lymphocyte counts was also reported in patients with unmutated immunoglobulin genes [11].

The safety profile of ibrutinib–treated patients in the current study seems consistent with previous reports, with most AEs being mild to moderate in severity and neutropenia, hypertension, pneumonia, and anemia being the most commonly reported grade 3–4 events [11,15,37,39]. Overall, 176 AEs were reported for 74 (54.4%) of the patients in the current study, with 46 of those 176 AEs being grade 3–4 AEs including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5) in most cases. The results from the RESONATE trial with up to 5 years of follow-up also showed that the safety profile of ibrutinib over time remains acceptable and manageable and that extended treatment with ibrutinib is tolerable with no long-term safety signals and a reduction in the majority of grade >3 AEs over time, while effective management of AEs during the first year of treatment is considered critical given the highest discontinuation rates within this period [16,24,40].

Consistent with previous real-life data obtained from ibrutinib–treated CLL patients that identified infection as the main cause of death and the reason for permanent discontinuation of ibrutinib [22,23], our findings revealed sepsis as the leading cause of death among ibrutinib–treated CLL patients. Nonetheless, it should be noted that in a systematic review and meta-analysis of phase III trials with 1227 patients (617 in the ibrutinib arm and 610 in the control arm), the authors concluded that there was no significant increase in the risk of infection associated with ibrutinib in patients with CLL [46].

Study Limitations

Although the occurrence of atrial fibrillation is generally between 7% and 15% in this age group in real-world analyses, our finding of atrial fibrillation occurrence of only 2% may be explained by the retrospective design of the current study. While the cardiac arrest (14%) and sudden death (3%) rates in our study population indicate a high rate of cardiac death (17%), none of these deaths were related to ibrutinib treatment and they were associated with the high proportion of elderly patients with comorbidities in the study cohort.

Conclusion

This real-life analysis of CLL patients confirms the favorable efficacy and safety profile of long-term ibrutinib treatment as reported by prospective clinical trials, while emphasizing the potential adverse impact of poorer ECOG performance status, having been heavily treated prior to ibrutinib initiation, and advanced Rai stages but not comorbidity, bulky disease, or del(17p) status on patient compliance, treatment responses, and survival outcomes.

Acknowledgments

This study was supported by Janssen Pharmaceutica Turkey. The authors would like to thank Prof. Şule Oktay, MD, PhD, and Çağla Ayhan, MD, from KAPPA Consultancy Training Research Ltd. (İstanbul, Turkey), who provided editorial support.

Ethics

Ethics Committee Approval: The study was conducted in full accordance with local good clinical practice guidelines and current legislations, while permission was obtained from the relevant institutional ethics committee for the use of patient data for publication purposes.

Authorship Contributions

Surgical and Medical Practices: A.T.; Concept: A.T.; Design: A.T.; Data Collection or Processing: A.T., F.P.T., S.S.D., H.D.D., E.K., E.G.Ü., I.Y., Ö.M., B.D., M.A.Ö., H.T., M.O., N.S., M.Y., V.O., A.K., Ö.Ö., G.Ç., S.D., İ.A., G.S., E.A.D., G.İ., M.A.U., G.Ö., S.A., B.T., İ.B., E.K., M.S., D.S.B., R.Y., V.Ö., A.K.G., B.S., Ş.E., O.M.A., A.B., M.H.D., A.A., A.Ü., A.S., E.G., D.Ç., B.F.; Analysis or Interpretation: A.T.; A.K.G., E.K., M.S., D.S.B., R.Y., V.Ö., A.K.G., B.S., Ş.E., O.M.A., A.B., M.H.D., A.A., A.Ü., A.S., E.G., D.Ç., B.F.; Literature Search: A.T.; Writing: A.T.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with clinical stage 1-2 chronic lymphocytic leukaemia in the original CLL International Prognostic Index, emphasizing the need for new risk models applicable to CLL patients treated with all currently approved targeted therapies [41,42,43,44].

In the current study, lymphocyte counts increased within the first month of treatment, followed by a gradual decrease starting from the second month. This is consistent with the transient increase in absolute lymphocyte count expected within the first few weeks of ibrutinib therapy, which may persist for several weeks of treatment and does not signify disease progression [24,45]. Nonetheless, some authors reported the association of prolonged treatment-related lymphocytosis with higher likelihood of ibrutinib responders to carry favorable prognostic markers (i.e., del13q and mutated IGHV) and a trend toward improved PFS [35,45], while more rapid and more frequent normalization of lymphocyte counts was also reported in patients with unmutated immunoglobulin genes [11].

The safety profile of ibrutinib–treated patients in the current study seems consistent with previous reports, with most AEs being mild to moderate in severity and neutropenia, hypertension, pneumonia, and anemia being the most commonly reported grade 3–4 events [11,15,37,39]. Overall, 176 AEs were reported for 74 (54.4%) of the patients in the current study, with 46 of those 176 AEs being grade 3–4 AEs including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5) in most cases. The results from the RESONATE trial with up to 5 years of follow-up also showed that the safety profile of ibrutinib over time remains acceptable and manageable and that extended treatment with ibrutinib is tolerable with no long-term safety signals and a reduction in the majority of grade >3 AEs over time, while effective management of AEs during the first year of treatment is considered critical given the highest discontinuation rates within this period [16,24,40].

Consistent with previous real-life data obtained from ibrutinib–treated CLL patients that identified infection as the main cause of death and the reason for permanent discontinuation of ibrutinib [22,23], our findings revealed sepsis as the leading cause of death among ibrutinib–treated CLL patients. Nonetheless, it should be noted that in a systematic review and meta-analysis of phase III trials with 1227 patients (617 in the ibrutinib arm and 610 in the control arm), the authors concluded that there was no significant increase in the risk of infection associated with ibrutinib in patients with CLL [46].

Study Limitations

Although the occurrence of atrial fibrillation is generally between 7% and 15% in this age group in real-world analyses, our finding of atrial fibrillation occurrence of only 2% may be explained by the retrospective design of the current study. While the cardiac arrest (14%) and sudden death (3%) rates in our study population indicate a high rate of cardiac death (17%), none of these deaths were related to ibrutinib treatment and they were associated with the high proportion of elderly patients with comorbidities in the study cohort.

Conclusion

This real-life analysis of CLL patients confirms the favorable efficacy and safety profile of long-term ibrutinib treatment as reported by prospective clinical trials, while emphasizing the potential adverse impact of poorer ECOG performance status, having been heavily treated prior to ibrutinib initiation, and advanced Rai stages but not comorbidity, bulky disease, or del(17p) status on patient compliance, treatment responses, and survival outcomes.

Acknowledgments

This study was supported by Janssen Pharmaceutica Turkey. The authors would like to thank Prof. Şule Oktay, MD, PhD, and Çağla Ayhan, MD, from KAPPA Consultancy Training Research Ltd. (İstanbul, Turkey), who provided editorial support.

Ethics

Ethics Committee Approval: The study was conducted in full accordance with local good clinical practice guidelines and current legislations, while permission was obtained from the relevant institutional ethics committee for the use of patient data for publication purposes.

Authorship Contributions

Surgical and Medical Practices: A.T.; Concept: A.T.; Design: A.T.; Data Collection or Processing: A.T., F.P.T., S.S.D., H.D.D., E.K., E.G.Ü., I.Y., Ö.M., B.D., M.A.Ö., H.T., M.O., N.S., M.Y., V.O., A.K., Ö.Ö., G.Ç., S.D., İ.A., G.S., E.A.D., G.İ., M.A.U., G.Ö., S.A., B.T., İ.B., E.K., M.S., D.S.B., R.Y., V.Ö., A.K.G., B.S., Ş.E., O.M.A., A.B., M.H.D., A.A., A.Ü., A.S., E.G., D.Ç., B.F.; Analysis or Interpretation: A.T.; Literature Search: A.T.; Writing: A.T.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with
chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.

2. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukaemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798.

3. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trenny M, Westermann A, Wendtner CM, Eichhorst BF, Staub P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.

4. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Söcker M, Schlag R, Vehling-Kaiser U, Köchling G, Plüger C, Gregor M, Plesner T, Trenny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016;17:928–942.

5. Fischer K, Bahlo J, Fink AM, Goede V, Herdling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herdling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Maritton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLLB trial. Blood 2016;127:208–215.

6. Zenz T, Busch R, Fink A, Winkler D, Fischer K, Bühler A, Hoth P, Fingerle-Rowson GR, Kneba M, Boettcher S, Jäger U, Mendila M, Wengner M, Lichter L, Hallek M, Döhner H, Stilgenbauer S. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLLB trial of the GCLLSG. Blood 2016;121:2467–2470.

7. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia: a 5-year experience. Blood 2018;131:1910–1919.

8. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian A, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019;133:1011–1019.

9. O'Brien S, Furman RR, Coutre S, Fink IW, Burger JA, Blum K, Sharmar J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chad, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018;131:1910–1919.

10. Burger JA, Furman RR, O'Brien S, Barretton JC, Kay NE, Reddy MM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kips TJ, Cymbalista F, Fucococ K, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JH, Chu AD, Fardis M, McCreivy J, Clow F, James D, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2018;379:2123–2132.

11. O'Brien S, Furman RR, Coutre S, Fink IW, Burger JA, Blum K, Sharmar J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chad, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018;131:1910–1919.

12. Burger JA, Furman RR, O'Brien S, Barretton JC, Kay NE, Reddy MM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kips TJ, Cymbalista F, Fucococ K, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JH, Chu AD, Fardis M, McCreivy J, Clow F, James D, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2018;379:2123–2132.

13. O'Brien S, Furman RR, Coutre S, Fink IW, Burger JA, Blum K, Sharmar J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chad, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018;131:1910–1919.
24. Wierda WG, Byrd JC, Abramson JS, Bilgami SF, Bociek G, Brander D, Brown J, Chan-an-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJJ, Ma S, Malek S, Mato A, Mosee C, Neppalli VT, Shadman M, Siddiqui T, Stephens D, Wagner N, Dayer MA, Sundar H, NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw 2019;17:12-20.

25. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745-2760.

26. Göcer M, Kurtğlo E. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Res 2020;55:206-212.

27. Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury CM, Albrecht C, Cymbalista F. Real-world results of ibrutinib in relapsed/refractory CLL in France: early results on a large series of 428 patients. Am J Hematol 2017;92:1666.e68.

28. Del Poeta G, Biagi A, Laurenti L, Ciarenza A, Pozzo F, Innocenti I, Postorino M, Rossi FM, Del Principe ML, Bomben R, de Fabritius P, Bruno A, Cantone D, Di Raimondo F, Zucchetto A, Gattee V. Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica 2021;106:2345-2353.

29. Machnicki MM, Górnika P, Pepek M, Szmyczak A, Iskierka-Jaźdżewska E, Steckiwiecz P, Bluszcz A, Rydzaniec M, Hus M, Płoski R, Makuch-Lasica H, Nowak G, Juszczyszyn P, Jamrozik A, Stoikos T, Pula B. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. Eur J Haematol 2021;109:320-326.

30. Ysebaert L, Aurran-Schleinitz T, Dartiges C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F. Real-world results of ibrutinib in relapsed/refractory CLL in France: early results on a large series of 428 patients. Am J Hematol 2017;92:1666.e68.

31. Ysebaert L, Quinquenel A, Bijou F, Ferrant E, Michallet AS; French Innovative Leukemia Organization (FILO) CLL Group. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 2019;134:641-644.

32. Del Poeta G, Biagi A, Laurenti L, Ciarenza A, Pozzo F, Innocenti I, Postorino M, Rossi FM, Del Principe ML, Bomben R, de Fabritius P, Bruno A, Cantone D, Di Raimondo F, Zucchetto A, Gattee V. Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica 2021;106:2345-2353.

33. Quintrix M, Kögl A, Rother A, Reiter M. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma 2019;60:2939-2945.

34. Göçer M, Kurtoğlu E. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Res 2020;55:206-212.

35. Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Dimou M, Iliakis T, Pardalis V, Bitsani C, Vassilakopoulos TP, Angelopoulou CS, Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Sundar H, NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw 2019;17:12-20.

36. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Gnoinski S, Devereux S, McCarty H, Coutre S, Quach H, Gaidano G, Masyvak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqui T, Polliazz L, Tam CS, Suri D, Cheng M, Chow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425-2437.

37. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heroy NA, Josephson AJ, Shaw Y, Bloté C, Zou Z, James DF. O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125:2497-2506.

38. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019;94:1353-1363.

39. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqui T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Steenman B, Morgan N, Liu Y, Chu HF, Hu F, James DF, Chu JS, Shadman M. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016;17:1409-1418.

40. Byrd J, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan S, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Pagel JM, Bociek G, Jones JA, Dai S, Voran RN, James DF, Brown JR. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the RESONATE study. J Clin Oncol 2017;35(15 Suppl):7510-7510.

41. Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Chumetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens D, Persky D, Brander D, Danilov AV. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leuk Res 2020;89:106302.

42. Kittai AS, Lunning M, Danilov AV. Relevance of prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep 2019;14:302-309.

43. Brander DM, Rhodes J, Pagel JM, Nabhan C, Tam CS, Jacobs R, Hill BT, Lamanna N, Lansigan F, Shadman M, Ujijani CS, Skarbnik AP, Cheson BD, Pu JJ, Sehgal AR, Barr PM, Allan JN, Beach DF, Bhavisht Patel, Pickins PV, Dwivedy Nasta S, Kendall K, Tuncer HD, Koch B, Furman RR, Mato AR. Applicability of the chronic lymphocytic leukemia (CLL)-JIP on patients treated with front-line ibrutinib in the real world: the case for new prognostic models. Blood 2017;130(15 Suppl 1):1719.

44. Soumerai JD, Ni A, Darif M, Londeh A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KB, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zeleznik AD. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukemia treated with targeted therapies or chemomunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol 2019;6:e366-e374.

45. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rasenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Chow F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:1810-1817.

46. Ball S, Das A, Vuthikraivit W, Edwards PJ, Hardwicke F, Short NJ, Borthakur G, Maiti A. Risk of infection associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. Clin Lymphoma Myeloma Leuk 2020;20:87-97.e5.